These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 2471453

  • 1. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S, Morishita T, Shibata J, Sato T.
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [Abstract] [Full Text] [Related]

  • 2. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S, Morishita T, Sagara K, Sato T, Motohara K, Matsuda I.
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [Abstract] [Full Text] [Related]

  • 3. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
    Tanaka Y, Kashiwagi T, Tsutsumi H, Nagasawa M, Toyama T, Ozaki S, Naito M, Ishibashi K, Azuma M.
    Hepatogastroenterology; 1999 Oct; 46(28):2464-8. PubMed ID: 10522021
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R, Wang B, Ding H, Shen H, Li Y, Chen X.
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [Abstract] [Full Text] [Related]

  • 5. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
    Tada H, Kagawa K, Hikita H, Takeuchi T, Ohta Y, Fukui S, Shintani H, Deguchi T, Okanoue T, Takino T.
    Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
    [Abstract] [Full Text] [Related]

  • 6. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
    Arima K, Kodama T, Suga M, Sakamoto H, Ohe Y, Yachi A.
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
    [Abstract] [Full Text] [Related]

  • 7. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
    Mohamedein A, Yousif-Kadaru AG, Ahmed SA, Saida H, Zaki ZA, Eldin, Fedail SS.
    East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
    Nakao A, Taniguchi K, Inoue S, Harada A, Nonami T, Watanabe K, Takagi H.
    Semin Surg Oncol; 1996 Sep; 12(3):160-3. PubMed ID: 8727604
    [Abstract] [Full Text] [Related]

  • 9. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group.
    Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R.
    Am J Gastroenterol; 2000 Apr; 95(4):1036-40. PubMed ID: 10763956
    [Abstract] [Full Text] [Related]

  • 10. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
    Aoyagi Y, Oguro M, Yanagi M, Mita Y, Suda T, Suzuki Y, Hata K, Ichii K, Asakura H.
    Cancer; 1996 May 01; 77(9):1781-6. PubMed ID: 8646674
    [Abstract] [Full Text] [Related]

  • 11. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
    Nakao A, Taniguchi K, Inoue S, Takeda S, Harada A, Nonami T, Watanabe K, Takagi H.
    Am J Gastroenterol; 1997 Jun 01; 92(6):1031-4. PubMed ID: 9177525
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
    Tanabe Y, Ohnishi K, Nomura F, Iida S.
    Am J Gastroenterol; 1988 Dec 01; 83(12):1386-9. PubMed ID: 2461655
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
    Sakizono K, Oita T, Shibata Y, Tamura A, Kasakura S.
    Rinsho Byori; 1998 Sep 01; 46(9):936-41. PubMed ID: 9800480
    [Abstract] [Full Text] [Related]

  • 17. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K, Watanabe T, Aikawa K, Toshima M, Shibasaki K, Aoyagi Y.
    Hepatogastroenterology; 1998 Sep 01; 45(23):1737-41. PubMed ID: 9840138
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma.
    Nomura F, Ishijima M, Kuwa K, Tanaka N, Nakai T, Ohnishi K.
    Am J Gastroenterol; 1999 Mar 01; 94(3):650-4. PubMed ID: 10086646
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.